Bavarian Nordic A/S
Vesterbrogade 149
Copenhagen
DK-1620
Tel: 45-3326-8383
Fax: 45-3326-8380
Website: http://www.bavarian-nordic.com/
Email: pw@bavarian-nordic.dk
207 articles about Bavarian Nordic A/S
-
The vaccine was effective against previous COVID-19 variants but lacked efficacy against new ones, the company announced Thursday, leaving the booster no commercially viable options.
-
The Danish company’s vaccine candidate met all co-primary endpoints in a late-stage study in adults and adolescents just months after publishing trial data for elderly patients, as it seeks to challenge Valneva.
-
Bavarian Nordic Reports Positive Phase 3 Topline Results for Chikungunya Virus Vaccine in Adults and Adolescents
8/6/2023
Bavarian Nordic A/S announced positive topline results from a randomized, double-blind, placebo-controlled Phase 3 clinical trial of its virus-like particle -based chikungunya virus vaccine candidate, CHIKV VLP in adults and adolescents aged 12 to 64 years of age.
-
Bavarian Nordic Receives USD 120 Million Contract for the Manufacturing of Smallpox and Mpox Vaccine from the U.S. Government
8/3/2023
Bavarian Nordic A/S announced that the U.S. Biomedical Advanced Research and Development Authority, part of the Administration for Strategic Preparedness and Response at the U.S. Department of Health and Human Services, has placed a new order valued at USD 120 million, primarily covering the manufacturing of new bulk product for the Company’s smallpox/mpox vaccine.
-
The Danish vaccine maker’s respiratory syncytial virus candidate did not meet all primary endpoints in a late-stage study in older adults and the company is discontinuing the program.
-
Bavarian Nordic Reports Phase 3 Topline Results for its COVID-19 Booster Vaccine Candidate
6/27/2023
Bavarian Nordic A/S (OMX: BAVA) today reported topline results from a Phase 3 non-inferiority clinical trial of ABNCoV2, a VLP-based, non-adjuvanted COVID-19 booster vaccine candidate.
-
Bavarian Nordic Reports Data from a Phase 3 Clinical Trial of its VLP-Based Chikungunya Virus Vaccine in Adults ≥65 Years of Age
6/20/2023
Bavarian Nordic A/S announced the initial safety and immunogenicity results from a randomized, double-blind, placebo-controlled Phase 3 clinical trial of a virus-like particle -based chikungunya virus vaccine candidate CHIKV VLP in healthy adults ≥65 years of age.
-
Emergent BioSolutions Finalizes Sale of Travel Health Business to Bavarian Nordic
5/15/2023
Emergent BioSolutions announced it has completed the sale of its travel health business to Bavarian Nordic.
-
Emergent BioSolutions Announces Sale of Travel Health Business to Bavarian Nordic for Up To $380 Million
2/15/2023
Emergent BioSolutions announced that it has entered into an agreement to sell its travel health business to Bavarian Nordic for a total value of up to $380 million, including potential future milestone payments.
-
Bavarian Nordic to Acquire Portfolio of Travel Vaccines from Emergent BioSolutions
2/15/2023
Bavarian Nordic A/S announced that it has entered into an agreement with Emergent BioSolutions Inc. to acquire two marketed travel vaccines, Vivotif® for the prevention of typhoid fever and Vaxchora® against cholera as well as a Phase 3 vaccine candidate for the prevention of Chikungunya virus for a total consideration of up to USD 380 million, including USD 270 million in an upfront payment and up to USD 110 million in future conditional milestone payments.
-
Alphalyse and Bavarian Nordic A/S significantly shorten the time necessary to document HCP impurities in COVID-19 vaccine candidate for Phase 3 clinical trial – through world’s first MS-based HCP analysis under GMP conditions
1/3/2023
Alphalyse has performed the world’s first GMP-certified mass spectrometry (MS)-based Host Cell Protein (HCP) analysis for product release testing for Phase 3 clinical trial, after being certified by the Danish Health and Medicines Authority to perform quality control of biological API using MS-based HCP analysis under GMP.
-
Bavarian Nordic Enters Agreement Valued up to USD 83 Million with the U.S. Department of Defense to Further Advance the Development of Equine Encephalitis Virus Vaccine
12/23/2022
Bavarian Nordic A/S announced a new agreement with the U.S. Department of Defense’s Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense, for the advanced development of MVA-BN® WEV, a prophylactic vaccine candidate against Western, Eastern and Venezuelan equine encephalitis virus, which can cause a rare, but potentially deadly mosquito-borne illness in humans.
-
Bavarian Nordic Completes Enrollment in Global Phase 3 Trial of RSV Vaccine Candidate for Older Adults
12/22/2022
Bavarian Nordic A/S (OMX: BAVA) announced today that the Company has completed the planned enrollment of subjects in the global, randomized, double-blind Phase 3 clinical trial of its investigational respiratory syncytial virus (RSV) vaccine candidate, MVA-BN ® RSV in adults ≥60 years of age.
-
Bavarian Nordic’s COVID-19 Booster Vaccine Candidate Demonstrates Durable Antibody Response Six Months After Vaccination in Phase 2 Clinical Trial
10/17/2022
Bavarian Nordic A/S announced the results of a six-month follow-up analysis from a Phase 2 clinical trial of ABNCoV2, a VLP-based, non-adjuvanted COVID-19 booster vaccine candidate.
-
Bavarian Nordic Awarded Ten-Year Contract Amendment valued up to USD 434 million for the Supply of Smallpox and Monkeypox Vaccine to Canada
9/20/2022
Bavarian Nordic A/S announced a revised contract with the Public Health Agency of Canada to supply doses of IMVAMUNE® smallpox vaccine at a value of approximately USD 234 million in addition to USD 180 million in contract options.
-
Bavarian Nordic Enters Supply Agreement with PAHO to Support Access to Monkeypox Vaccines in Latin America and the Caribbean
8/24/2022
Bavarian Nordic A/S announced an agreement with the Pan American Health Organization to facilitate equitable access to the Company’s monkeypox vaccine for countries in Latin America and the Caribbean.
-
Cases of monkeypox infections reported in the latest viral outbreak have surpassed 14,000 in the U.S., according to the CDC. Some scientists believe the outbreak was predictable.
-
Cases of monkeypox are growing at an alarming rate and Bavarian Nordic, the company that owns one of the two approved vaccines, may no longer be able to keep up.
-
Bavarian Nordic Expands Capacity with U.S. Contract Manufacturer for Filling of Smallpox/Monkeypox Vaccines
8/18/2022
U.S. FDA approved facility operated by Grand River Aseptic Manufacturing will assist in filling of already manufactured bulk vaccine to expedite deliveries of monkeypox vaccines to the U.S.
-
The measures will allow San Francisco and New York to coordinate efforts across different agencies and raise the public's awareness to curb the spread of monkeypox.